Imatinib Rowex (Imatinib)

Imatinib selectively blocks the ATP‑binding sites of BCR‑ABL, c‑KIT, and platelet‑derived growth factor receptors (PDGFR). By inhibiting these tyrosine kinases, the drug prevents downstream signaling that promotes uncontrolled cell proliferation, survival, and angiogenesis, leading to reduced tumor growth and, in many cases, tumor regression.

The dosage of Imatinib Rowex is individualized and determined by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and concomitant therapies. Healthcare providers follow established clinical guidelines and may adjust the dose during treatment to balance efficacy and tolerability.

The safety of Imatinib during pregnancy or lactation has not been definitively established. It is generally advised to avoid use unless the potential benefit to the mother outweighs the possible risk to the fetus or infant. Women of childbearing potential should discuss contraception and treatment options with their oncologist before initiating therapy.

To place an order, submit an enquiry on the Imatinib Rowex product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details, and necessary import documentation.

Imatinib was the first BCR‑ABL tyrosine kinase inhibitor approved for CML and remains a standard first‑line option. Compared with newer agents such as dasatinib or nilotinib, imatinib has a well‑characterized safety profile and extensive long‑term data, though some patients may achieve deeper molecular responses with second‑generation inhibitors. Choice of therapy depends on disease risk, tolerance, and physician assessment.

Imatinib Rowex tablets should be stored at ambient temperature, below 25 °C, in their original packaging. Protect the product from moisture, direct sunlight, and excessive heat. Do not store in bathrooms or near kitchen appliances. Keep out of reach of children and unused tablets should be discarded according to local regulations.

Imatinib Rowex is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed. Patients should follow the dosing schedule provided and attend regular follow‑up appointments for monitoring.

The most serious adverse events include hepatotoxicity, severe myelosuppression (such as neutropenia, anemia, or thrombocytopenia), and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome or toxic epidermal necrolysis. Cardiac dysfunction, including heart failure, has also been reported. Prompt reporting of symptoms and regular laboratory monitoring are essential to mitigate these risks.

Imatinib Rowex is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. Caution is advised for individuals with pre‑existing severe hepatic impairment, uncontrolled cardiac disease, or those receiving strong CYP3A4 inducers that may reduce drug exposure. Pregnant or breastfeeding women should avoid use unless the benefits clearly outweigh the risks, and it should be prescribed only under specialist supervision.